Vijaya Diagnostic Centre Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Soft quarter, no alarm: Organic revenue growth (ex-PH) slowed to ~18% because February posted single-digit growth, but management found no structural cause and reaffirmed the 15%+ CAGR trajectory.
• Gross margin reset is structural: Wellness now at 15% of revenue and growing, which permanently dilutes gross margin even as it flows through to EBITDA; management told investors to model this as the new normal.
• The hub rollout is the FY26 story: Six hubs opened in the last two months across Pune, Bengaluru and Kolkata, with ~10 more coming this year; the upfront cost will depress EBITDA by 1–2% for 2–3 quarters before centers break even.
• Hyderabad keeps taking share: Existing centers grew double digits while competitors #2, #3 and #4 stagnated, all without Vijaya adding capacity in the city for two years.
• What to watch next quarter: Whether the February softness was a one-off or the start of a trend, the pace of breakeven at the six new hubs, and the margin recovery path once those centers stabilize.

The Q4 Softness: One Weak Month, No Clear Cause

• February was the culprit: The month posted single-digit growth, pulling down what is normally a strong quarter for healthcare; management identified no concrete reason, citing possible distractions from Kumbh Mela, travel, Ramzan and Ugadi falling in March.
• No structural read-through: Q2 and Q4 are historically better quarters for the sector, and management treated the February dip as seasonal noise rather than a demand signal.
• Pune revenue dipped by design: The company consciously exited some B2B aggregator tie-ups where payments were becoming problematic; the revenue loss was minimal and intentional.

Suprita Reddy: "building that relationship is typically what we get that one year or two for breakeven. Otherwise, there are multiple ways in how we can probably fast forward that. But no, we would like to take that time, bring them into the center, showcase what we can do, invest that time into a conversation and build that brand out and that's how the model has been has worked out well" [17-18]

Hub Expansion: The FY26 Investment Cycle

• Six hubs launched in 60 days: Two each in Pune, Bengaluru and West Bengal went live; three more in West Bengal are expected within 3–4 months, and two Tier-2 hubs in AP/Telangana are slated for H2 FY26.
• ~10 hubs planned for FY26: Capex guided at ₹140–150 crore to fund the rollout, with spokes to follow once hubs stabilize.
• Breakeven target is 3–4 quarters: Management takes a 2–3 month buffer and then targets one year; Ongole already broke even (revenue above breakeven for three months), and Nizamabad is close, awaiting a PCPNDT license.
• Bengaluru is a market test: Two hubs in opposite corners of the city will validate whether the Hyderabad go-to-market playbook travels; early signals are positive, and pricing is comparable to Hyderabad.
• Kolkata build-out accelerates in FY27: With two hubs already operating, two just launched and three more coming, the city will see a significant spoke expansion next year.

Suprita Reddy: "These two centers that we've chosen, in fact, are in two different corners of Bangalore. It's also to test out whether our go-to-market strategy in Hyderabad works likewise in Bangalore. And I should definitely say that it's looking very positive."

Margin Mechanics: The Gross Margin Reset and Near-Term EBITDA Drag

• Wellness is structurally compressing gross margin: At 15% of revenue and growing (higher in Pune), wellness carries discounted pricing; management explicitly told investors to model this contraction as the new normal, with only marginal improvement if the wellness share dips to 14%.
• The offset is flow-through to EBITDA: Because the same center services wellness and non-wellness customers, the gross margin dilution does not create a parallel EBITDA problem.
• FY26 EBITDA will dip before it recovers: The first 2–3 quarters will carry a 1–2% EBITDA margin hit from six subsidiaries starting simultaneously, plus corporate-level resources and digital/IT initiatives; management expects normalization by FY26 exit.
• PH margins optically depressed: 95% of PH revenue comes from six centers, but capacity just increased 70–75% with new Pune additions; one-off training and hiring costs charged to the P&L pushed Q4 PH margins to 29% versus a normalized ~35%.
• Depreciation will outpace growth initially: For the first 2–3 quarters, depreciation and amortization expenses will run ahead of network expansion growth, then normalize as centers break even.
• A 1–2% price increase is coming: It applies only to select tests and is calibrated to add 1–2% to total revenue, not a broad repricing.

Competitive Position: Hyderabad as the Proof of Concept

• Market share gains without capacity adds: Vijaya’s existing Hyderabad centers grew double digits while the city’s #2, #3 and #4 players did not grow, despite Vijaya adding no new capacity there in two years.
• The differentiator is breadth under one roof: Management attributes the share gain to quality infrastructure, technology, doctor talent and comprehensive test availability, all at market pricing; in Tirupati, the center stood out against 7–10 existing MRI machines by offering quality that competitors did not match at the same price.
• The B2C model is non-negotiable: Management explicitly rejected aggregator or distributor models that separate sample collection from the patient relationship, framing the in-center experience as core to brand-building.

Sivaramaraju Vegesna: "If you take player #2, #3, #4 of Hyderabad, they are not growing in spite of we not adding any capacity in the last two years in Hyderabad, they are growing at a much faster pace than them."

Growth Composition and Revenue Drivers

• 15%+ CAGR reaffirmed for three years: The trajectory remains intact, with 1–2% from value (pricing) and the rest from volume.
• New centers contribute ~4% to overall growth: But volume contribution from them is only 2–3% in year one because new hubs are dominated by advanced radiology, which generates higher revenue per test but lower initial test counts.
• Wellness is a growth lever, not just a margin diluter: Digital efforts are inching wellness share up even in core geographies; Pune already runs above 15% wellness, and the full-year consolidation of Pune (versus three months last year) boosted the reported mix.
• Hyderabad’s revenue share will dip below 70% as investments outside the core market scale up.
• Average realization per test is flat: Capacity added in Tier-2 locations carries slightly lower pricing than Hyderabad; going forward, Pune, Bengaluru and Kolkata pricing is more aligned with Hyderabad (within ~5%).

Organizational Build-Out and Digital Investments

• CTO onboarded: A new chief technology officer with 25+ years at technology-driven companies has joined; the first project is a new CRM implementation in the current financial year.
• Mid-to-senior hires across functions: Multiple additions made to support parallel geographic expansion.
• Digital spend will grow slightly in FY26 and beyond, reflecting the CRM rollout and other IT initiatives.
• No diversification into dialysis: Management was explicit that the company remains purely in diagnostics.

Guidance & Commitments

Key Metrics